Prescription Drugs · Oncology Therapeutics
AstraZeneca revenue, results and funding
AstraZeneca filed revenue of $58.7B for 2025.
Data updated Nov 20, 2026 · Back to the company report
$58.7BRevenue, 2025
$10.2BNet income, 2025
70,600Employees, 2019
AZNNasdaq Stockholm AB
Results by year
| Year | Revenue | Net income | Total assets | Employees | LANG_CR_S_M_TAX_PAID | LANG_CR_S_M_TAX_EXPENSE | LANG_CR_S_M_DIVIDENDS | LANG_CR_S_M_BUYBACKS | LANG_CR_S_M_CAPEX | LANG_CR_S_M_STAFF_COSTS | LANG_CR_S_M_SBC | LANG_CR_S_M_RND | LANG_CR_S_M_OPERATING_INCOME | LANG_CR_S_M_CASH | LANG_CR_S_M_DEBT | LANG_CR_S_M_ACQUISITIONS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $58.7B | $10.2B | $114.1B | – | $2.8B | $2.2B | $5B | $521M | $2.8B | $14.5B | $719M | $14.2B | $13.7B | $5.7B | $24.7B | – |
| 2024 | $54.1B | $7B | $104B | – | $2.8B | $1.7B | $4.6B | $81M | $1.9B | $13.7B | $660M | $13.6B | $10B | $5.5B | $26.5B | – |
| 2023 | $45.8B | $6B | $101.1B | – | $2.4B | $938M | $4.5B | $0 | $1.4B | $12.3B | $579M | $10.9B | $8.2B | $5.8B | $22.4B | – |
| 2022 | $44.4B | $3.3B | $96.5B | – | $1.6B | −$792M | $4.4B | $0 | $1.1B | $11.5B | $619M | $9.8B | $3.8B | $6.2B | $23B | – |
| 2021 | $37.4B | $112M | $105.4B | – | $1.7B | −$380M | $3.9B | $149M | $1.1B | $10.3B | – | $9.7B | $1.1B | $6.3B | $28.1B | – |
| 2020 | $26.6B | $3.2B | $66.7B | – | $1.6B | $772M | $3.6B | – | $961M | $8.2B | – | $6B | $5.2B | $7.8B | $17.5B | – |
| 2019 | $24.4B | $1.3B | $61.4B | 70,600 | $1.1B | $321M | $3.6B | – | $979M | $7.6B | – | $6.1B | $2.9B | $5.4B | $15.7B | – |
| 2018 | $22.1B | $2.2B | $60.7B | – | $537M | −$57M | $3.5B | – | $1B | $7B | – | $5.9B | $3.4B | $4.8B | $17.4B | – |
| 2017 | $22.5B | $3B | $63.4B | 64,600 | $454M | −$641M | $3.5B | – | $1.3B | $6.5B | – | $5.8B | $3.7B | $3.3B | $15.6B | $1.5B |
| 2016 | $23B | $3.5B | $62.5B | 61,100 | $412M | $146M | $3.6B | – | $1.4B | $6.3B | – | $5.9B | $4.9B | $5B | $14.5B | $2.6B |
| 2015 | $24.7B | $2.8B | $60.1B | – | $1.4B | $243M | $3.5B | – | $1.3B | $6.1B | – | $6B | $4.1B | $6.2B | $14.1B | $2.4B |
Sources: SEC, Wikidata, ESEF
Rounds and grants
| Year | Round | Amount |
|---|---|---|
| 2027 | Grant | $377k |
| 2027 | Grant | $351k |
| 2026 | Grant | $377k |
| 2026 | Grant | $377k |
| 2026 | Grant | $150k |
| 2026 | Venture | not stated |
| 2025 | Grant | $941k |
| 2025 | Grant | $351k |
| 2025 | Grant | $343k |
| 2025 | Grant | $317k |
| 2024 | Grant | $317k |
| 2024 | Grant | $317k |
| 2024 | Grant | $317k |
| 2024 | Grant | $249k |
| 2023 | Grant | $634k |
| 2023 | Grant | $634k |
| 2023 | Grant | $264k |
| 2022 | Grant | $634k |
| 2022 | Grant | $562k |
| 2022 | Grant | $54k |
| 2021 | Grant | $854k |
| 2021 | Grant | $327k |
| 2021 | Grant | $305k |
| 2021 | Grant | $305k |
| 2021 | Grant | $300k |
| 2021 | Grant | $152k |
| 2020 | Grant | $305k |
| 2020 | Grant | $305k |
| 2020 | Grant | $305k |
| 2020 | Grant | $260k |
| 2019 | Grant | $1M |
| 2019 | Grant | $1M |
| 2019 | Grant | $609k |
| 2019 | Grant | $327k |
| 2019 | Grant | $327k |
| 2019 | Grant | $305k |
| 2018 | Grant | $295k |
| 2018 | Grant | $295k |
| 2018 | Grant | $104k |
| 2017 | Grant | $285k |
| 2017 | Grant | $285k |
| 2016 | Grant | $759k |
| 2016 | Grant | $570k |
| 2016 | Grant | $285k |
| 2016 | Grant | $285k |
| 2016 | Grant | $285k |
| 2015 | Grant | $435k |
| 2015 | Grant | $285k |
Sources: funding announcements, SEC filings, grant registers
How to cite
AstraZeneca, Financials. Alion, Nov 20, 2026. https://alion.io/company/astra-zeneca/financials
